Repurposing an Osteoporosis Drug for β Cell Regeneration in Diabetic Patients.
Replenishing the lost or dysfunctional insulin-producing β cell mass in diabetic patients could slow down or reverse disease progression. Kondegowda et al. (2015) now show that osteoprotegerin and denosumab, inhibitors of the receptor activator of the NF-κB Ligand (RANKL) pathway and osteoclast activation, stimulate human β cell proliferation and therefore possess therapeutic potential.